Cabaletta Bio Inc (CABA) Hedge Fund & Institutional Holdings (Q2 2026)

CABA ranks #3759 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

145 institutions disclose a position in CABA, but none treat it as a major bet — even Bain Capital Life Sciences Investors, LLC, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

Jennison Associates LLC has added to its CABA position for two straight quarters, increasing it by $42.8M to reach $62.3M today.

Barclays PLC has trimmed its CABA position for two straight quarters, cutting it by $344.3K while still holding $139.0K.

CABA is up 8.2% today, and institutions have been net buyers of $241.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CABA reported a net loss of $167.9M in its latest fiscal year.

• Not yet profitable — net loss of $167.9M in the latest fiscal year
• Net income declined year over year, from -$115.9M to -$167.9M
• Operating cash flow was negative, using $131.1M in cash
• Current ratio of 2.77x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.47x equity — within a conventional range